कंपनी का अवलोकन
Ascendis Pharma A/S operates as a biopharmaceutical entity dedicated to developing and commercializing TransCon-based therapies designed to address unmet medical needs across Europe, the United States, and international markets. The company functions within the Healthcare sector and specifically within the Biotechnology industry, a segment characterized by high research and development costs and a focus on innovative drug delivery systems for treating complex conditions. Ascendis Pharma A/S holds a significant market capitalization of $14.84 billion and generated annual revenue of $720.13 million while employing a workforce of 1,189 individuals. These financial metrics indicate that the company has secured a substantial valuation relative to its current revenue base, reflecting market confidence in its pipeline of therapies such as SKYTROFA for pediatric growth hormone deficiency and YORVIPATH for oncology, despite the company's current stage of commercial development.
वित्तीय स्वास्थ्य
The company reported revenue of $720.13 million for the trailing twelve months, yet this revenue generated a net income of -$228,034,000 and an EBITDA of -$131,415,000, revealing a substantial gap where operating expenses significantly outpace gross profit generation. Despite the negative net income and EBITDA figures, the company maintains a free cash flow of $164.71 million, which provides a critical buffer of liquidity to fund ongoing operations, research initiatives, and potential acquisitions without immediate reliance on external financing. The gross margin stands at 86.8%, indicating high pricing power and efficient manufacturing of its pharmaceutical products, while the operating margin is merely 1.0% and the profit margin is -31.7%, highlighting that high fixed costs and R&D expenditures are eroding profitability before reaching the bottom line. In terms of balance sheet leverage, Ascendis Pharma holds $616.04 million in cash against $871.79 million in debt, resulting in a debt-to-equity ratio that is not applicable (N/A) due to the absence of shareholder equity, suggesting a leveraged position typical for capital-intensive biotech firms. The current ratio is 1.04, which indicates that the company's current assets are just slightly above its current liabilities, signaling a tight but manageable short-term liquidity position that requires careful working capital management. Furthermore, the return on equity is not applicable (N/A) and the return on assets is -6.9%, metrics that reflect the challenges in generating positive returns on invested capital when the company is in a heavy investment phase with negative earnings.
मूल्यांकन आकलन
Ascendis Pharma A/S has a trailing twelve-month P/E ratio that is not applicable (N/A) due to negative earnings, while the forward P/E ratio is 19.59, implying that the market prices the stock based on anticipated future profitability rather than current historical performance. The price-to-book ratio is -78.72, a negative figure that indicates the market values the company's intangible assets, such as intellectual property and pipeline potential, far above its accounting book value, which is heavily impacted by accumulated losses. Alternative valuation metrics show a price-to-sales ratio of 20.61 and an EV/EBITDA of -114.84, suggesting that investors are willing to pay a significant premium for sales growth potential despite the lack of current earnings, a common valuation approach for biotechnology companies with promising pipelines. The stock has experienced a wide trading range over the past year, with a 52-week high of $248.60 and a 52-week low of $124.06, placing the current trading price within a volatile band that reflects shifting sentiment regarding the company's clinical trial outcomes. The beta value is 0.48, indicating that the stock's price volatility is less than half that of the broader market, making it a lower-beta investment that may offer stability relative to larger market indices during periods of general equity market turbulence.
Growth & Income
Revenue growth for the trailing twelve months is 42.3%, while earnings growth is not applicable (N/A) due to the company's current negative earnings status, implying that top-line expansion is the primary driver of value creation rather than immediate earnings improvement. The company does not pay a dividend, evidenced by a dividend yield of not applicable (N/A) and a payout ratio of 0.0%, which means the company retains all its free cash flow to reinvest in research and development rather than distributing income to shareholders. This reinvestment strategy is standard for biotechnology firms in the growth phase, where capital allocation towards expanding clinical programs and manufacturing capacity is prioritized over income generation for investors. Overall, the company's growth and income profile is characterized by rapid revenue expansion and a zero-dividend policy that supports long-term value creation through the commercialization of its TransCon platform therapies.